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time trade-off for Polish population were used to evaluate inﬂu-
ence of demographic, social and cultural factors on EQ-5D utility
value. Based on additional data concerning demographic and
lifestyle factors collected, adjusted modeling was performed
using GRETL and WinBugs software. Impact of this factors was
analyzed by directly including variables in the model, as well as
adjusting for variables corresponding interaction between the
factors and health domain. RESULTS: Data from 230 interviews
(5280 valuations) were analyzed. Preliminary random effects
model was developed, with constant and N3 factor, all coefﬁ-
cients statistically signiﬁcant, R2 equal to 0.37 and value -0.647
for 33,333 health state. After adjusting base model for gender
and smoking no inﬂuence on utility value was observed. Includ-
ing the interaction terms between age (0–1 variable deﬁned as
above/below median of 38 years) and belief in life after death
(deﬁned as strong agreement) with health domains (level 3)
proved to be statistically signiﬁcant and improved model R2 up to
0.40. Direct inﬂuence of belief in life after death on the utility
value of health states was signiﬁcant, R2 equal to 0.38 and
coefﬁcient value 0.16. CONCLUSIONS: Demographic and cul-
tural factors inﬂuence the utility value of health in Polish popu-
lation. According to results based on preliminary data belief in
life after death signiﬁcantly reduces utility loss.
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OBJECTIVES: Patient-Reported Outcomes (PRO) are routinely
used to measure disease severity, perceived treatment impact, or
patient attitude toward treatment. However, adherence can only
partially be explained by clinical and PRO variables alone. Our
objective is to develop a generic Acceptability measure assessing
how patients balance out between advantages and disadvantages
of long-term treatments. It could be used in future adherence
studies through pharmacies. METHODS: A literature review
was conducted in biomedical databases using keywords related
to acceptability, perceptions, motivations and barriers linked to
treatment. From 434 abstracts reviewed, 29 articles containing
relevant concepts were retained to form the initial conceptual
model of Acceptability. Exploratory interviews were performed
with 5 pharmacists and 18 patients. They were recorded, tran-
scribed word-for-word and systematically analysed. Concepts
captured were organised into a detailed model used as a basis for
the development of the test-version of the Acceptability question-
naire. RESULTS: The initial model of Acceptability included 6
global concepts: treatment perception, disease perception, judge-
ment, behaviour, individual characteristics and medical context.
The pharmacist interviews conﬁrmed this model. The patient
interviews conﬁrmed the inﬂuence of treatment attributes on
their Acceptability, but invalidated the concept of a judgment.
The model adopted for the conceptual content of the Acceptabil-
ity questionnaire covers 23 attributes organised in three major
domains: efﬁcacy, safety and convenience. Patients will be asked
to rate how the treatment suits them, for each of the attributes.
CONCLUSIONS: Qualitative research on Acceptability conﬁrms
the relevance of the concept for patients, but it also shows that
judging whether a drug is good or not is left to the expertise of
the health care professional. Appropriate wording was critical
during item generation to capture the information in a way that
make sense for the patients. After the testing and revision of the
questionnaire, it will be able to be included in adherence studies.
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OBJECTIVES: Treatment Satisfaction (SATMED-Q) is a generic
PRO instrument measuring Treatment satisfaction with medi-
cines in chronic health conditions. Several multisample analysis
are carried out in order to assess the stability of the question-
naire structure across of different types of patients, and to dis-
cover possible differences in dimension correlations for different
drug treated pathologies. METHODS: Four samples of patients
with different known pathologies following regular medication
treatment were gathered from specialized units, and primary
attention centres: hypertensive, drug-refractory-epilepsy sub-
jects, caregivers of patients with dementia of the Alzheimer type
and a normative sample. Exploratory factor analyses on each
separate sample were carried out to assess sample speciﬁc struc-
tures. Multi-sample conﬁrmatory factor analysis was used to
assess the degree of agreement between sample structures using
the known theoretical structure. Congruence statistics were also
used with exploratory structures. RESULTS: A total of 2777
patients were gathered: 1,025 hypertensive patients -47%
women, 63 (11.3) years old-, 768 epileptic patients -65%
women, 41 (13.4) years old-, 842 Alzheimer patients care-
givers -63% women, 78 (6,8) years old-, and the normative
sample used to develop the SATMED-Q composed by 442
patients of different pathologies -50% women, 62 (13.6) years
old-. The theoretical 6-factor solution identiﬁed in the original
instrument was attained in all sample speciﬁc exploratory
analyses. The multi-sample conﬁrmatory analysis matched the
6-dimensional solution but usual goodness of ﬁt problems with
large sample sizes were found. Sample speciﬁc conﬁdence inter-
vals for factor loadings and factor correlations were obtained.
Congruence statistics were reasonable, but were not able to
explain differences in the obliqueness of factors. Meaningful
differences in dimension correlations between samples were
found. CONCLUSIONS: The structure of the SATMED-Q
questionnaire is shown to be stable across different type of
treatments and patients, but the relations between dimensions
vary depending on the pathology studied.
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BACKGROUND: In the last decade various studies have been
published that reported the costs of non-compliance. However,
the quality of those studies has been questioned. OBJECTIVES:
To systematically review and critically appraise the literature to
identify the main methodological limitations related to estimat-
ing and reporting costs of non-compliance in patients with dia-
betes, schizophrenia, rheumatoid arthritis and osteoporosis.
METHODS: A literature review was conducted using PubMed,
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